st-067
Recombinant proteinexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 8, 2021 (NCT04787042)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Microsatellite Instability · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Interleukin-18ANTAGONIST
IL18 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314892 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07098364 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2025 | Simcha, University of Washington |
| NCT06588660 | Phase 1 | Feb 1, 2025 | Simcha, University of Washington |
| NCT06492707 | Phase 1 | Sep 23, 2024 | Simcha, University of Washington |
| NCT04787042 | Phase 1/Phase 2 (Phase 2) | Jul 8, 2021 | Simcha |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Simcha | For profit | 4 | 1 | 2 | 2021 |
| University of Washington | Academic/Hospital | 3 | 3 | 2 | 2024 |
2 organizations
Page 1 / 1